- Home
- AGL vs ELVN Comparison
AGL vs ELVN Comparison
Compare AGL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- ELVN
- Stock Information
- Founded
- AGL 2016
- ELVN 2016
- Country
- AGL United States
- ELVN United States
- Employees
- AGL 1076
- ELVN N/A
- Industry
- AGL Managed Health Care
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- ELVN Health Care
- Exchange
- AGL Nasdaq
- ELVN Nasdaq
- Market Cap
- AGL 923.1M
- ELVN 927.8M
- IPO Year
- AGL 2021
- ELVN 2020
- Fundamental
- Price
- AGL $2.15
- ELVN $21.71
- Analyst Decision
- AGL Hold
- ELVN Strong Buy
- Analyst Count
- AGL 20
- ELVN 4
- Target Price
- AGL $4.47
- ELVN $37.25
- AVG Volume (30 Days)
- AGL 5.0M
- ELVN 412.1K
- Earning Date
- AGL 05-06-2025
- ELVN 05-14-2025
- Dividend Yield
- AGL N/A
- ELVN N/A
- EPS Growth
- AGL N/A
- ELVN N/A
- EPS
- AGL N/A
- ELVN N/A
- Revenue
- AGL $5,988,958,000.00
- ELVN N/A
- Revenue This Year
- AGL N/A
- ELVN N/A
- Revenue Next Year
- AGL $10.11
- ELVN N/A
- P/E Ratio
- AGL N/A
- ELVN N/A
- Revenue Growth
- AGL 23.07
- ELVN N/A
- 52 Week Low
- AGL $1.50
- ELVN $13.30
- 52 Week High
- AGL $7.73
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- AGL 32.82
- ELVN 65.82
- Support Level
- AGL $2.09
- ELVN $20.98
- Resistance Level
- AGL $2.37
- ELVN $22.64
- Average True Range (ATR)
- AGL 0.15
- ELVN 1.24
- MACD
- AGL 0.04
- ELVN 0.62
- Stochastic Oscillator
- AGL 14.58
- ELVN 93.56
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.